SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

Phase 2 Recruiting 35 enrolled The First Affiliated Hospital with Nanjing Medical University

NaSingle-groupOpen-labelTreatment

The purpose of this study is to evaluate the efficacy and safety of SVRd in NDMM patients presenting with extramedullary disease.

Evaluation	Drug	Modality	Dose	Route
Subject	Bortezomib	Small molecule	1.3 mg/m2	Intravenous
Subject	Dexamethasone	Small molecule	20 mg	Oral
Subject	Lenalidomide	Other / unclassified	25 mg	Oral
Subject	Selinexor	Other / unclassified	60 mg	Oral